|
|
||||||||
1From the Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan; the 2Departments of Ophthalmology and 3Immunology, Kurume University School of Medicine, Fukuoka, Japan.
PURPOSE. To determine whether patients with Vogt-Koyanagi-Harada (VKH) disease have immune responses specific to the melanocyte antigens tyrosinase and gp100.
METHODS. T-cell clones (TCCs) were established from cells infiltrating the aqueous humor and from peripheral blood mononuclear cells (PBMCs) of patients with VKH. The target cells were LDR4-transfected cells (HLA-DRB1*0405). The TCCs were cocultured with LDR4 in the presence of tyrosinase (tyrosinase450-462: SYLQDSDPDSFQD), gp100 (gp10044-59: WNRQLYPEWTEAQRLD), or a control peptide. The immune response was evaluated by cytokine production. The responding melanocyte peptide-specific VKH-TCCs were characterized by an immunofluorescence method with flow cytometry. A search was made for molecular mimicry among tyrosinase450-462, gp10044-59, and exogenous antigens, such as viruses, by database screening.
RESULTS. Cells infiltrating the eye and PBMCs in HLA-DR4+ (HLA-DRB1*0405, 0410) patients with VKH contained a population of CD4+ T lymphocytes that recognized tyrosinase and gp100 peptides and produced RANTES and IFN-
in response to the two peptides. The T cells were active memory Th1-type lymphocytes, and they recognized the tyrosinase peptide and produced IFN-
in response to HLA-DRB1*0405+ melanoma cells. Cytomegalovirus envelope glycoprotein H (CMV-egH290-302) had high amino acid homology with the tyrosinase peptide. In addition, some of the VKH-TCCs recognized CMV-egH290-302 peptide, as well as the tyrosinase peptides.
CONCLUSIONS. In VKH there are tyrosinase and gp100 peptide-specific T cells that can mediate an inflammatory response. Such melanocyte antigen-specific T cells could be associated with the cause and pathology of VKH disease.
This article has been cited by other articles:
![]() |
F. Prignano, C. M. Betts, and T. Lotti Vogt Koyanagi Harada disease and vitiligo: Where does the illness begin? J. Electron Microsc. (Tokyo), January 3, 2008; (2008) dfm036v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sugita, H. Takase, C. Taguchi, and M. Mochizuki The Role of Soluble TNF Receptors for TNF-{alpha} in Uveitis Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3246 - 3252. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |